课题基金 / 基金详情

项目摘要

项目成果

David A Hildeman的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):维持T细胞稳态对免疫系统的正常功能至关重要。经胸腺细胞选择后,T细胞进入外周淋巴器官并作为初始细胞维持在那里。当初始T细胞经历抗原驱动的扩张并获得效应功能时,稳态会发生短暂的破坏。然后效应T细胞要么经历凋亡(即在群体水平上收缩),要么存活成为记忆细胞。这个过程是至关重要的:它重置T细胞稳态,促进保护性免疫,并限制自身免疫。虽然凋亡的两种途径(死亡受体和Bcl-2调控)都可以影响T细胞的稳态,但最近的数据表明,在常见γ链细胞因子的动态调控下,Bcl-2调控的途径对体内T细胞的稳态至关重要。Bim是一种非冗余的、促凋亡的含有bh -3的分子,对于限制初始T细胞、效应T细胞和较小程度的记忆T细胞的存活至关重要。然而,效应T细胞存活并进入记忆室的机制尚不清楚。这些知识对于我们在治疗上操纵效应T细胞蜕变为记忆T细胞的能力至关重要。我们发现,随着细胞在激活阶段的转变,抗凋亡的Bcl-2家族成员对对抗Bim至关重要,似乎发生了变化。在初始记忆T细胞和静止记忆T细胞中,Bcl-2对对抗Bim和促进生存至关重要。在Bcl-2减少或缺失的情况下,Mcl-1可能拮抗Bim,但效果不如Bcl-2。总的来说,这些新的初步数据表明,通过Stat5到Bcl-2和/或Mcl-1的细胞因子驱动信号调节效应T细胞对bim介导的死亡的易感性。该模型的一个可测试的预测是,细胞因子驱动的Bim拮抗剂应该驱动效应T细胞存活并增强病原体清除。本提案中的实验将测试三个相互关联的假设:(i)当Bcl-2水平低时,Mcl-1在效应T细胞中拮抗Bim; (ii)根据细胞因子环境,Stat5向Bcl-2和/或Mcl-1发出的信号对效应T细胞在体内的存活至关重要;(iii)细胞因子可用性的增强可导致效应T细胞存活和病原体清除的增加。这项研究的长期目标是确定分子靶点,这些靶点可以用于提高T细胞存活率(即改善疫苗接种)或降低T细胞存活率(即抑制自身免疫性疾病或移植排斥反应)。公共卫生相关性:维持T细胞稳态对免疫系统的正常功能至关重要。感染后,大多数抵抗感染的T细胞死亡,而一些留下来,成为“记忆”细胞,并提供防止再次感染的保护。控制这些T细胞死亡/存活的机制尚不清楚,但对我们理解保护性免疫至关重要。我们发现单个分子Bim限制了小鼠记忆T细胞的数量。本研究探讨了T细胞正常对抗Bim的机制,以及如何操纵T细胞对抗Bim以提高免疫记忆。
英文摘要
DESCRIPTION (provided by applicant): Maintenance of T cell homeostasis is critical for normal functioning of the immune system. After thymocyte selection, T cells enter the peripheral lymphoid organs and are maintained there as naive cells. Transient disruption of homeostasis occurs when naive T cells undergo antigen-driven expansion and acquire effector functions. Effector T cells then either undergo apoptosis (i.e., contraction at the population level) or survive to become memory cells. This process is crucial: it resets T cell homeostasis, promotes protective immunity, and limits autoimmunity. While both pathways of apoptosis (death receptor and Bcl-2 regulated) can affect T cell homeostasis, recent data point to the Bcl-2-regulated pathway, under dynamic regulation by common gamma chain cytokines, as being critical for T cell homeostasis in vivo. Bim is a non-redundant, pro-apoptotic BH-3-containing molecule critical for limiting survival of naive, effector, and to a lesser extent memory T cells. However, the mechanism(s) by which effector T cells survive and enter the memory compartment remain unclear. Such knowledge is crucial for our ability to therapeutically manipulate the metamorphosis of effector T cells to memory T cells. We have found that as cells transition through stages of activation, the anti-apoptotic Bcl-2 family members critical for combating Bim appear to change. In naive and resting memory T cells, Bcl-2 is critical to antagonize Bim and promote survival. In situations where Bcl-2 is decreased or absent, Mcl-1 likely antagonizes Bim, but does so less efficiently than Bcl-2. Collectively, these new preliminary data suggest a model in which cytokine-driven signals through Stat5 to Bcl-2 and/or Mcl-1 modulate susceptibility of effector T cells to Bim-mediated death. A testable prediction of this model is that cytokine-driven antagonism of Bim should drive effector T cell survival and enhance pathogen clearance. Experiments in this proposal will test three interrelated hypotheses: (i) Mcl-1 antagonizes Bim in effector T cells when Bcl-2 levels are low (ii) depending upon the cytokine milieu Stat5 signaling to Bcl-2 and/ or Mcl-1 is critical for survival of effector T cells in vivo; and (iii) enhancement of cytokine availability can lead to increased effector T cell survival and pathogen clearance. The long-term goal of this research is to identify molecular targets that could be exploited therapeutically to enhance T cell survival (i.e. to improve vaccination) or to decrease T cell survival (i.e. suppress autoimmune disease or transplant rejection). PUBLIC HEALTH RELEVANCE: Maintenance of T cell homeostasis is critical for normal functioning of the immune system. After an infection, the majority of T cells that have fought the infection die, while some remain, become "memory" cells, and provide protection from re-infection. Mechanisms that control the death/survival of these T cells remain unclear, but are critical to our understanding of protective immunity. We have found that a single molecule Bim limits the numbers of memory T cells in mice. This proposal explores mechanism(s) by which T cells normally combat Bim and how they can be manipulated to combat Bim to improve immunologic memory.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathogenesis and therapeutic targeting of immune disorders
  • 批准号:
    9308845
  • 项目类别:
  • 资助金额:
    $14.21万
  • 财政年份:
    2016
  • 负责人:
    David A Hildeman
  • 依托单位:
Pathogenesis and therapeutic targeting of immune disorders
  • 批准号:
    9925180
  • 项目类别:
  • 资助金额:
    $13.15万
  • 财政年份:
    2016
  • 负责人:
    David A Hildeman
  • 依托单位:
Pathogenesis and therapeutic targeting of immune disorders
  • 批准号:
    9149365
  • 项目类别:
  • 资助金额:
    $14.06万
  • 财政年份:
    2016
  • 负责人:
    David A Hildeman
  • 依托单位:
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire
海外基金